(Q37101731)

18 August 2017

Examining the efficacy of adjunctive aripiprazole in major depressive disorder: a pooled analysis of 2 studies (English)

1 reference

major depressive disorder

18 August 2017

1 reference

2

Madhukar H Trivedi

1 reference

18 August 2017

Michael E Thase

1

1 reference

18 August 2017

J Craig Nelson

3

1 reference

18 August 2017

Maurizio Fava

4

1 reference

18 August 2017

Rene Swanink

5

1 reference

18 August 2017

Quynh-Van Tran

6

1 reference

18 August 2017

Andrei Pikalov

7

1 reference

18 August 2017

Huyuan Yang

8

1 reference

18 August 2017

Berit X Carlson

9

1 reference

18 August 2017

Ronald N Marcus

10

1 reference

18 August 2017

Robert M Berman

11

1 reference

18 August 2017

language of work or name

1 reference

1 January 2008

1 reference

Primary Care Companion to the Journal of Clinical Psychiatry

18 August 2017

1 reference

18 August 2017

10

1 reference

18 August 2017

6

1 reference

18 August 2017

440-447

1 reference

Safety and Tolerability of Adjunctive Aripiprazole in Major Depressive Disorder: A Pooled Post Hoc Analysis (studies CN138-139 and CN138-163).

18 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2644484

Clinical evidence and potential neurobiological underpinnings of unresolved symptoms of depression

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2644484

The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study.

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2644484

The role of dopamine in the pathophysiology of depression

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2644484

A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, and fluoxetine in treatment-resistant major depressive disorder

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2644484

Interaction of the novel antipsychotic aripiprazole with 5-HT1A and 5-HT 2A receptors: functional receptor-binding and in vivo electrophysiological studies

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2644484

Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2644484

Dopamine D2-like receptors and the antidepressant response

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2644484

Pharmacological approaches to the treatment of residual symptoms

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2644484

Current status of augmentation and combination treatments for major depressive disorder: a literature review and a proposal for a novel approach to improve practice.

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2644484

Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2644484

Potential mechanisms of action of atypical antipsychotic medications in treatment-resistant depression and anxiety.

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2644484

Aripiprazole augmentation in treatment-resistant depression

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2644484

Aripiprazole as an augmentor of selective serotonin reuptake inhibitors in depression and anxiety disorder patients

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2644484

Response of the norepinephrine system to antidepressant drugs.

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2644484

Invited review: the evolution of antidepressant mechanisms

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2644484

The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R)

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2644484

Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology.

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2644484

Diagnosis and definition of treatment-resistant depression

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2644484

World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders, Part 1: Acute and continuation treatment of major depressive disorder

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2644484

The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2644484

Clinical guidelines for the treatment of depressive disorders. II. Principles of management

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2644484

Augmentation of antidepressants with atypical antipsychotic medications for treatment-resistant major depressive disorder: a meta-analysis

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2644484

Does incomplete recovery from first lifetime major depressive episode herald a chronic course of illness?

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2644484

Aripiprazole augmentation of selective serotonin reuptake inhibitors for treatment-resistant major depressive disorder

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2644484

Aripiprazole augmentation of antidepressants for the treatment of partially responding and nonresponding patients with major depressive disorder

27 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2644484

Residual symptoms in depressed patients who respond acutely to fluoxetine.

27 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2644484

The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study

27 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2644484

Risperidone for treatment-refractory major depressive disorder: a randomized trial

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2644484

In vivo actions of aripiprazole on serotonergic and dopaminergic systems in rodent brain.

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2644484

Treatment of residual anxiety symptoms with adjunctive aripiprazole in depressed patients taking selective serotonin reuptake inhibitors

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2644484

In vivo effects of aripiprazole on cortical and striatal dopaminergic and serotonergic function

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2644484

Effects of serotonin (5-hydroxytryptamine, 5-HT) reuptake inhibition plus 5-HT(2A) receptor antagonism on the firing activity of norepinephrine neurons

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2644484

Major depressive disorder: a prospective study of residual subthreshold depressive symptoms as predictor of rapid relapse.

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2644484

A prospective 12-year study of subsyndromal and syndromal depressive symptoms in unipolar major depressive disorders.

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2644484

Assessing psychiatric impairment in primary care with the Sheehan Disability Scale

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2644484

Practice guideline for the treatment of patients with major depressive disorder (revision). American Psychiatric Association

3 September 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/19287552

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Progressive attenuation of the firing activity of locus coeruleus noradrenergic neurons by sustained administration of selective serotonin reuptake inhibitors

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/19287552

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Residual symptoms after partial remission: an important outcome in depression

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/19287552

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.4088/PCC.V10N0603

1 reference

18 August 2017

1 reference

18 August 2017

PubMed publication ID

19287552

1 reference